Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

Geoffrey Y. Ku, MD
Published: Thursday, Feb 09, 2017



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Researchers of a phase III study tested almost 500 patients who had previously received 2 or more chemotherapy treatments. These patients were treated with either nivolumab (Opdivo), the PD-1 antibody, or placebo.

There was a 12-month overall survival rate of 27% in these patients versus the 11% in patients who had received placebo. For the first time, this phase III evidence confirmed that these drugs are active in patients with gastric and esophageal cancers, says Ku.



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Researchers of a phase III study tested almost 500 patients who had previously received 2 or more chemotherapy treatments. These patients were treated with either nivolumab (Opdivo), the PD-1 antibody, or placebo.

There was a 12-month overall survival rate of 27% in these patients versus the 11% in patients who had received placebo. For the first time, this phase III evidence confirmed that these drugs are active in patients with gastric and esophageal cancers, says Ku.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x